
Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Your AI-Trained Oncology Knowledge Connection!


Published: December 13th 2016 | Updated: